Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy

F. Pisani, A. Fazio, G. Oteri, C. Artesi, B. Xiao, E. Perucca, R. Di Perri

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.

Original languageEnglish
Pages (from-to)130-132
Number of pages3
JournalActa Neurologica Scandinavica
Volume90
Issue number2
Publication statusPublished - 1994

Fingerprint

Viloxazine
Antidepressive Agents
Epilepsy
Drug-Related Side Effects and Adverse Reactions
Seizures
Placebos
oxcarbazepine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. / Pisani, F.; Fazio, A.; Oteri, G.; Artesi, C.; Xiao, B.; Perucca, E.; Di Perri, R.

In: Acta Neurologica Scandinavica, Vol. 90, No. 2, 1994, p. 130-132.

Research output: Contribution to journalArticle

Pisani, F. ; Fazio, A. ; Oteri, G. ; Artesi, C. ; Xiao, B. ; Perucca, E. ; Di Perri, R. / Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. In: Acta Neurologica Scandinavica. 1994 ; Vol. 90, No. 2. pp. 130-132.
@article{bad123c004024304a277ae16b0e283f0,
title = "Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy",
abstract = "The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11{\%} increase in the plasma concentration of MHD (p = 0.003) associated with a 31{\%} fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.",
author = "F. Pisani and A. Fazio and G. Oteri and C. Artesi and B. Xiao and E. Perucca and {Di Perri}, R.",
year = "1994",
language = "English",
volume = "90",
pages = "130--132",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy

AU - Pisani, F.

AU - Fazio, A.

AU - Oteri, G.

AU - Artesi, C.

AU - Xiao, B.

AU - Perucca, E.

AU - Di Perri, R.

PY - 1994

Y1 - 1994

N2 - The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.

AB - The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.

UR - http://www.scopus.com/inward/record.url?scp=0027930972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027930972&partnerID=8YFLogxK

M3 - Article

C2 - 7801739

AN - SCOPUS:0027930972

VL - 90

SP - 130

EP - 132

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 2

ER -